Indications

• Acute Myeloid Leukemia (AML) (see Acute Myeloid Leukemia, [[Acute Myeloid Leukemia]])
• Multiple Myeloma (see Multiple Myeloma, [[Multiple Myeloma]])

---

Pharmacology

• Thalidomide Derivative

---

Administration

• xxx

---

Adverse Effects

Pulmonary Manifestations

• Hypersensitivity Pneumonitis-Like Syndrome (see Interstitial Lung Disease-Etiology, [[Interstitial Lung Disease-Etiology]])
• Cryptogenic Organizing Pneumonia (see Cryptogenic Organizing Pneumonia, [[Cryptogenic Organizing Pneumonia]])
• Cytokine Release Syndrome (see Cytokine Release Syndrome, [[Cytokine Release Syndrome]])

Hematologic Manifestations

• Myelosuppression/Pancytopenia (see Pancytopenia, [[Pancytopenia]])
• Hypercoagulable State (see Hypercoagulable States, [[Hypercoagulable States]])

Other Manifestations

• Teratogenicity: likely teratogenic, although studies are unclear
• Hepatotoxicity (see xxxx, [[]])
• Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (see Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, – [[Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis]])

---

References

• Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide. Chest 2007 vol. 131 no. 5 1572-1574
• Lenalidomide-induced interstitial lung disease. Pharmacotherapy. 2010 Mar;30(3):325
• Acute Lung Toxicity Related to Pomalidomide. Chest August 2011 vol. 140 no. 2 529-533
• Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. September 1, 2009 vol. 94 no. 9 1266-1273